Introduction
The role of mitochondrial dysfunction in cancer has been a subject of great interest from various aspects. Mitochondrial defects have long been suspected to play an important role in the development of cancer. Over 50 years ago, Warburg pioneered research into the involvement of mitochondrial respiratory defects in cancer, and proposed a mechanism to explain how these defects evolve during carcinogenesis. Warburg hypothesized that a key event in carcinogenesis involved the development of an injury to the mitochondrial respiratory machinery, resulting in a compensatory increase in glycolysis, leading to lactic acidosis (Warburg, 1930 (Warburg, , 1956 . Lactic acidosis is a typical biochemical hallmark of mitochondrial diseases and is widely used in the diagnosis of mitochondrial encephalomyopathies (DiMauro et al., 1985) . Many groups have confirmed that the majority of cancer cells harbor somatic mutations in the mitochondrial genome which may represent the 'injury of mitochondria' described by Warburg (Polyak et al., 1998; Yeh et al., 2000; Liu et al., 2001; Parrella et al., 2001; Carew and Huang, 2002; Maximo et al., 2002; Tan et al., 2002) . Comprehensive scanning of somatic mitochondrial DNA (mtDNA) mutations has revealed that functionally relevant point mutations in mitochondrial RNA and polypeptide-encoding genes were present in 50% of patients (Linnartz et al., 2004) . Thus, cancer cells seem to harbor pathogenic mutations in mtDNA as well as neutral mutations.
However, despite the close association between carcinogenesis and somatic mutations, it remained unclear whether these somatic mutations are contributors to the development of tumors or whether they simply arise as part of the secondary effects in cancer. In any case, a high frequency of mtDNA alterations in cancer and their presence in the early stages could be exploited as clinical markers for early cancer detection (Fliss et al., 2000; Nishikawa et al., 2001) . Mitochondrial DNA alterations detected in cerebrospinal fluid may be used as sensitive markers to monitor disease progression and predict relapse (Wong et al., 2003) .
The high frequency of mtDNA mutations and the rapid proliferation of cancer cells with no physiological advantage has been proposed to account for the accumulation of somatic mutations in mtDNA. In fact, extensive computer modeling suggests that if a single mtDNA mutation occurs in a tumor progenitor cell, mtDNA homoplasmy (i.e., a pure population of mutant mtDNA molecules) can be achieved entirely by chance through unbiased mtDNA replication and sorting during cell division without selection for physiological advantage (Coller et al., 2001) . This model can explain the occurrence of neutral mutations in cancer mtDNA.
In this review article, we will discuss a method developed to clarify the role of pathogenic mutations in mtDNA through the investigation of mitochondrial diseases. Here, we applied this method to study the contribution of mutant mtDNA in cancer by focusing on mtDNA and concluded that pathogenic mutations contribute to the promotion of tumorigenesis. Moreover, the association between mtDNA mutations and development of anticancer drug tolerance will also be addressed.
Methods that clarify contributions of mitochondrial DNA
How to investigate the role of mitochondrial DNA The cell contains a nuclear genome and a mitochondrial genome. The human mitochondrial genome encodes two ribosomal RNA, 22 transfer RNA and 13 polypeptides. All the polypeptides are subunits belonging to the respiratory chain or the ATP synthase complex. The remaining hundreds of mitochondrial proteins are encoded by nuclear genes, synthesized in cytosol and post-translationally imported into mitochondria (Attardi and Schatz, 1988) . All components involved in the maintenance, expression and regulation of the mitochondrial genetic system are encoded in nuclear genes. Thus, even though mitochondrial alterations have been described, the role of the mitochondrial genome in promoting malignant transformation is not understood. Additionally, cross-talk between these two genomes should be considered (Ohta, 2003; Nakashima-Kamimura et al., 2005) . Thus, when investigating the role of the mitochondrial genome, we must precisely distinguish the contribution of the mitochondrial genome from that of the nuclear genome. In particular, it would be important to understand whether many of these mutations occur during the initiation and/or development of cancer. When approaching this question, it is important to compare mtDNA in the context of identical nuclear backgrounds.
Previously, we developed a method to exclude the contribution of the nucleus to clarify the role of mutant mtDNA derived from patients with mitochondrial disorders. We constructed a hybrid cell with a common nucleus and mtDNA of interest derived from patients and could clarify that several mutations in mtDNA are conclusively responsible for the diseases. Since the cytoplasm containing mtDNA was fused with a cell lacking mtDNA, we call it a 'cybrid' instead of a 'hybrid' (Hayashi et al., 1991a; Attardi et al., 1995) .
Establishment of cells lacking mitochondrial DNA
Before referring to cybrids, we will explain the method to completely deplete mtDNA. Since human mtDNA encodes only 13 subunits belonging to the respiratory chain or the ATP synthase complex, mammalian cells can survive without mitochondria if essential metabolic substrates are supplied. ATP can be synthesized in cytosol by glycolysis. In addition to energy metabolism, mitochondria have many other roles that are essential for living cells. Thus, mitochondria are essential for eukaryotes and cannot be excluded. However, it is possible to deplete mtDNA in cells. Indeed, yeast strains (Saccharomyces cervisiae) lacking mtDNA, termed r0 are easily established when supplying fermentable carbon sources. However, yeast mitochondria could not be removed. Subsequently removal of mtDNA was also achieved in avian cells (Desjardins et al., 1986) . Human r0 cells could be isolated by long exposure to ethidium bromide (EtBr), which is a strong inhibitor of mitochondrial RNA polymerase Attardi, 1989: Hayashi et al., 1991b) . Since RNA functions as a primer for mitochondrial DNA replication, EtBr strongly inhibits DNA replication. For a long time, mouse r0 cells could not be isolated because they became resistant to EtBr at a high frequency (Hayashi et al., 1990) . Instead they were isolated by long exposure with an anticancer drug (Inoue et al., 1997) . Human r0 cells are cultured in a medium containing pyruvate and uridine because pyruvate is converted to lactate coupled with an oxidation of NADH to NAD þ , which is required for glycolysis and because uridine synthesis requires energized mitochondrion (King and Attardi, 1989) . Currently, r0 cells are often used as a model of a mtDNA mutation, but one should remember that it is highly possible to introduce considerable mutations into nuclear genes of r0 cells by long exposure to EtBr. Thus, their parental cells are unsuitable for r0 cell control.
No method for the direct introduction of mitochondrial DNA So far, no technique to introduce full length or a fragment of mtDNA into mammalian cells has been established. Such an approach could enable to introduce a mutation of interest into a specific cancer cell to clarify the role of mutant mtDNA. On the other hand, it is possible to introduce a fragment of yeast mtDNA into yeast with a particle gun. Namely, metal particles with a fragment of mtDNA are shot mechanically into mitochondria across the plasma, and mitochondrial outer and inner membranes at high speed (Klein and Fitzpatrick-McElligott, 1993) . Since yeast mitochondria have a strong recombination system, the fragment is inserted into yeast mtDNA by recombination (D'Aurelio et al., 2004) . However, human mitochondria have very low mtDNA recombination ability. In addition, mammalian mtDNA is easily degraded if not enveloped by mitochondrial transcriptional factor A (Tfam) (Takamatsu et al., 2002) ; hence it is difficult to overcome the problems. A revolutionary method is yet to be established for manipulating mtDNA in human cells.
Construction of cybrids
A cybrid is constructed by fusing cytoplasm carrying mtDNA of interest with a r0 cell (Figure 1) (Moraes et al., 2001) . Cytoplasm is prepared from enucleated cells (Hayashi et al., 1991a) ; alternatively platelets or synaptosomes can be used as a cytoplasmic source (Inoue et al., 1997) . Since a chemical enucleating method by the exposure to actinomycin D has recently been reported for the transfer of mtDNA to r0 cells (BayonaBafaluy et al., 2003) , it has become easier to prepare sources of mitochondria from cancer cells.
Cybrids enabled us to confirm that mutations in mtDNA are necessarily and sufficiently responsible for decreases in mitochondrial activity. A deletion mutation was shown to be responsible for the decline in chronic progressive external ophthalmoplegia (CPEO) subgroup mitochondria (Hayashi et al., 1991a) . A point mutation in the tRNA Lys gene at nucleotide position 8344 was confirmed to be responsible for the other subgroup myoclonic epilepsy associated with ragged-red fibers (MERRF) (Chomyn et al., 1991) . A point mutation in the tRNA Leu(UUR) gene at nucleotide position 3243 or 3271 was confirmed as the cause of the mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) subgroup of mitochondrial disease (King et al., 1992; Hayashi et al., 1993) . The cybrid method is at present widely used to determine whether a nucleotide substitution is pathogenic or the result of a simple polymorphism.
Direct contribution of mutants mitochondrial DNA revealed by the cybrid method
Transplantation of cybrids into nude mice To explore the role of pathogenic mitochondrial mutations in the development of cancer, we applied the cybrid method with a HeLa nucleus and mtDNA mutated at nucleotide position 8993 (Holt et al., 1990; Tatuch et al., 1992) or position 9176 (Nakano et al., 2003) in the subunit 6 gene of ATP synthase (MATP6). These mutants are derived from patients with mitochondrial encephalomyopathy. However, they can be reasonably used as models of cancer mtDNA because of the reported downregulation of ATP synthase b-subunit expression in liver, kidney, colon, squamous oesophageal and lung carcinomas, as well as in breast and gastric adenocarcinomas (Cuezva et al., 2002 (Cuezva et al., , 2004 Isidoro et al., 2004) . To compare mutant and wild-type cybrids in terms of their potential to form tumors, we transplanted the cybrid cells subcutaneously into nude mice. Settlement frequencies from the mutant cybrids were higher than those from the wild type. All the tumors derived from mutant cybrids were larger and grew faster than those from wild-type cybrids ( Figure 2 ) . At the same time, the other group reported that cybrids with the same 8993 mutation grew to larger tumors in the same transplantation system (Petros et al., 2005) . We would like to emphasize that two independent groups confirmed this result by the cybrid method.
Moreover, to confirm that mutant cybrid tumors had faster growth, we transplanted a mixture (1:1) of mutant and wild-type cybrids into nude mice. The proportion of mutant mtDNA in the tumor increased progressively, and eventually, mutant mtDNA entirely replaced the wild-type mtDNA. Thus, wild-type mtDNA appeared to be selectively excluded from the mixture of wild-type and mutant cybrids. Taken together, mtDNA mutant cells have an apparent advantage to form tumors as compared to wild-type cells, providing an explanation for why homoplasmic mtDNA mutations are found in many tumors with mitochondrial dysfunction .
Use of cells lacking mitochondrial DNA
The transplantation of cybrids into nude mice has been employed previously to investigate the role of mtDNA in tumorigenesis. r0 cells and cybrid cells with wild-type mtDNA were transplanted into nude mice. Tumors were formed by the cybrids containing wild-type mtDNA but not by r0 cells (Hayashi et al., 1992) . In contrast, another group reported that r0 cells could form tumors Contribution of mutant mtDNA in tumorigenesis S Ohta (Morais et al., 1994) . However, neither study compared cybrids with wild-type or mutant mtDNA. In most mitochondrial diseases, associated with severe pathogenity mutant mtDNA exists heteroplasmically, while mild mutant mtDNA exists homoplasmically (Lightowlers et al., 1997) . Since most somatic mtDNA mutants in cancer reach homoplasmy, the mutations seem to have rather mild pathogenity. Since r0 cells may be too weak to survive, r0 cells may not be suitable as a model in the investigation of tumorigenesis.
On the other hand, the transient depletion of mtDNA influenced the expression of various nuclear genes involved in tumorigenic and invasive phenotypes (Amuthan et al., 2001 ).
How to distinguish direct effects by mutant mitochondrial DNA from secondary nuclear mutations Possibility of secondary mutations in nuclear genes Since nuclear mutations as well as mtDNA mutations arise somatically at a high frequency in cancer, the potential role of mtDNA mutations in cancer development, genetic instability, and disease progression requires a careful and comprehensive investigation. Secondary mutations in nuclear genes may occur to enhance carcinogenesis during culture or transplantation after the construction of cybrids. If so, it cannot be concluded that mtDNA directly contributes to tumorigenesis, and mutant mtDNA may simply play a role as a mutagenesis of nuclear genes. Mutant mtDNA enhances the generation of reactive oxygen species (ROS), from the mitochondrial electron transport chain, that induces mutations in nuclear genes as well as mitochondrial genes. To address this issue, it would be useful to replace a mutation of mtDNA into wild type and then to examine whether potential effects on tumorigenesis are lost or remain in cybrids. However, as mentioned above, a method for manipulating mtDNA is not available. Instead of manipulating mtDNA, the import of mitochondrial proteins from cytosol into mitochondria was considered to complement mitochondrial dysfunction.
Import of mitochondrial proteins
Most mitochondrial proteins are encoded by nuclear genes, synthesized in cytosol as precursors and imported into mitochondria. Most precursor proteins are equipped with a target presequence at their N-terminus. Even if passenger proteins are not mitochondrial proteins, most of them can be imported into mitochondria when fused with a target presequence (Attardi and Schatz, 1988) .
Mitochondrial genes encoding proteins are composed of mitochondrial codons. Thus, at first, codons of mitochondrial genes were converted into universal codons, and genes equipped with a target sequence gene were introduced into the nucleus and expressed in cytosol. The mitochondrial protein produced was imported into mitochondria and complemented the dysfunction derived from the mitochondrial disease (Figure 3) . Additionally, the subunit 4 gene of complex I (ND4), a mitochondrial gene, complemented the dysfunction . It is unknown how universally applicable this method is. Larger and/or more hydrophobic proteins may be difficult to import into mitochondria even when a target presequence is equipped to the protein.
Expression of a mitochondrial protein from the nucleus via cytosol We explored whether mutant mtDNA induced secondary mutations in nuclear genes that accelerate the proliferation of mutant cybrids. As mentioned above, technology to transfect mtDNA into mammalian cells has yet to be established. Alternatively, we transfected into mutant cybrids a nuclear version of MTATP6 whose codons had been converted into universal codons (NuATP6) . The gene contained an N-terminal presequence to target the protein to mitochondria and a FLAG tag for ease of immunodetection. We isolated stable transfectants with NuATP6 and confirmed the expression of NuATP6 by immunostaining with anti-FLAG antibodies in cybrids carrying the mitochondrial T8993G mutation. Conversely, we transfected a nuclear version of MTATP6 possessing the T8993G mutation (muATP6) into wild-type cybrids. As expected, stable transfections of NuATP6 in mutant cybrids partially restored oxygen consumption, whereas the introduction of muATP6 into wild-type cybrids decreased oxygen consumption. The cybrid transfectants were transplanted into nude mice and followed the tumor growth. The results indicated that the expression of functional MTATP6 slowed down tumor growth as compared to tumors derived from mock-transfected cybrids; whereas defective MTATP6 cybrids promoted Figure 3 Expression of the mitochondrial ATP synthase subunit 6 (MATP6) nuclear transgene in the cytosol and its import into the mitochondria. The MATP6 gene was converted to the nuclear version by substituting mitochondrial codons with universal codons, fused with a mitochondrial-targeting presequnce (MTS) and a FLAG tag (FLAG) for detection. The gene, wild type or mutant, was transfected into the nucleus and its product functioned in mitochondria by importing from cytosol.
Contribution of mutant mtDNA in tumorigenesis S Ohta tumor growth as compared to tumors derived from mock-transfected cybrids. FLAG-positive mutant cybrids expressing wild-type MATP6 resulted in smaller tumors, indicating that functional MTATP6 conferred a disadvantage in tumor growth as compared with the expression of defective MTATP6. These results clearly show that tumorigenicity depends upon the mitochondrial function, but not upon secondary mutations in the nuclear genome.
To recapitulate in vivo the growth advantage conferred by muATP6 compared to wild-type cybrids, we mixed 1:1 ratio cybrid transfectants having functional MATP6 with mock ones, or conversely, cybrid transfectants having mutant MATP6 with mock transfectants, and transplanted the mixtures into nude mice. Since transfection genes were equipped with a FLAG tag, the transfectants were easily detected. Cybrids possessing mutant MATP6-FLAG became numerous in tumors. Conversely, T8,993G mutant cybrids with wild-type MATP6-FLAG were reduced in tumor promotion.
Taken together, these observations consistently showed that the growth advantage of in vivo tumors depends on the decline in the MATP6 function, and not upon secondary effects from the nucleus.
How to increase mutant mitochondrial DNA after a somatic mutation
Dual roles of reactive oxygen species in the development and prevention of cancer As shown above, pathogenic mutations in mtDNA give an advantage in tumor growth and overcome wild-type mtDNA in the promotion of tumors. We will now discuss how to increase mutant mtDNA (Figure 4) .
The high frequency of mtDNA alterations in cancer and their presence in the early stages of disease could be exploited as clinical markers for early cancer detection (Fliss et al., 2000) . ROS may be a cause for inducing the mutations. Superoxide anion radicals (O 2 À ) are derived from oxygen molecules by accepting electrons that leaked from the respiratory chain. In turn, they are converted into hydrogen peroxide spontaneously or by the catalytic activity of manganese-dependent superoxide dismutase (Mn-SOD). The resulting hydrogen peroxide is then converted into a hydroxyl radical by Fenton reaction in the presence of Fe 2 þ or Cu þ . Hydroxyl radicals are the most reactive and toxic, possessing the potential to oxidize lipids, proteins and DNA, leading to somatic mutations. Multiple and progressive steps of mutations in genes including oncogenes and tumor suppressors are considered to contribute to neoplatsic transformation. Thus, hydroxyl radicals are a strong candidate as an inducer of cancer. Superoxide and hydrogen peroxide are sources of hydroxyl radicals, while superoxide and hydrogen peroxide play several important roles by activating many signals for regulating homeostasis (Lee et al., 1998; Evans et al., 2000; McCord, 2000; Michiels et al., 2002) . In particular, superoxide and hydrogen peroxide induce apoptosis signals (Matsuzawa et al., 2005) , which may protect against cancer. Thus, one must remember that ROS may have a dual role as an inducer of as well as a protector against cancer depending upon the development stage of cancer.
Drift of mutant mitochondrial DNA toward homoplasmy
Many mutant mtDNAs found in cancer cells exhibit homoplasmy. It is impossible to mutate all mtDNA molecules at once. Then it follows, that mutant mtDNA must overcome the wild-type DNA in a cell. Fusion between cancer cells with and without mutant mtDNA resulted in homoplasmy (Polyak et al., 1998) , suggesting the mutant mtDNA had overcome the wild-type in a cell. On the other hand, in the case of mutant mtDNA derived from a patient with a MELAS subgroup, heteroplasmic mutant mtDNA with a point mutation at nucleotide position 3243 was drifted toward homoplasmy in cybrids (Yoneda et al., 1992) . However, the results differed among cybrids with different nuclear backgrounds (Dunbar et al., 1995) . Thus, the behavior of mtDNA toward homoplasmy depends upon the nucleus.
When mtDNA with a long deletion was transferred into cybrids under the HeLa nucleus from a fibroblast, the deletion mutant gradually increased. However, when a galactose medium lacking glucose was supplied, cybrids with the deletion mutant increased by only a certain extent probably due to a low-energy production (Hayashi et al., 1991a) . In this case, the deletion mutant mtDNA may be advantageous in mtDNA replication, and a sufficient energy production by glycolysis does not affect cell growth in glucose-rich medium. On the other hand, the mutant mtDNA gives a disadvantage to cellgrowth in glucose-deficient medium because sufficient energy cannot be produced by glycolysis as well as oxidative phospholylation. Thus, the balance between mtDNA replication and cell proliferation seems to determine the ratio of mutant and wild-type mtDNA. The molecular mechanism of this drift is unknown. One   Figure 4 A model explaining the increase in mutant mitochondrial DNA (mtDNA) during the development of cancer.
Step 1: A mutation occurred in an mtDNA molecule, where blue and red circles indicate wild-type mtDNA and mutant mtDNA, respectively.
Step 2: Mutant mtDNA increased toward homoplasmy in a cell.
Step 3: Mutant mtDNA reached homoplasmy. During the increase in mtDNA, tolerance to a low-energy condition may be achieved.
Step 4: Cells with homoplasmic mutant mtDNA overcome cells with wild-type mtDNA. Since cells with mutant mtDNA are insensitive to apoptosis, cells with wild-type mtDNA relatively decrease by apoptosis.
Step 5: Cells containing homoplasmic mutant mtDNA predominantly remained.
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S Ohta possibility is a replication advantage of mutant mtDNA; alternatively, mutant mtDNA may increase by the clonal expansion of a mutant mtDNA molecule. Since the mechanism of mtDNA replication is under reconsideration (Yasukawa et al., 2005) , the molecular mechanism of how mutant mtDNA increases during cancer development will be understood in the near future.
Apparent increase of the growth of mutant cybrids, but no proliferation advantage Next, we consider how mutant cells with homoplasmic mutant mtDNA overcome wild-type cells. Mutant cells with defective mitochondria should be disadvantageous in an energy production by declining oxidative phosphorylation. However, upregulation glycolytic pathway may be complementary to the increase of mutant mtDNA in a cell (Xu et al., 2005) . This apparent growth is faster in mutant cybrid cells than wild-type cells. To confirm the growth advantage of mutant cybrids, mutant and wild-type cybrids were mixed in a 1:1 ratio and the relative proportions of the mutant and wild-type mtDNAs were assessed in the mixed cultures. As a result, the relative content of mutant mtDNA progressively increased and eventually replaced the wildtype mtDNA.
To exclude the possibility that secondary mutations in nuclear genes led to a growth advantage in culture, the nuclear version of MATP6 was introduced into mutant cybrids, and the resulting transfectants grew significantly slower than control mutant cybrids mock transfected with an empty plasmid. Conversely, when the mutant version was transfected into wild-type cybrids, the resulting transfectants increased significantly faster than control mock-transfected wild-type cybrids. Moreover, to confirm the effect of the transfection of the nuclear version of MATP6 on the transfectant increase, we mixed the transfectants and mock transfectants in a 1:1 ratio. The number of NuATP6 FLAG-positive cybrids decreased relative to the mock transfected. Conversely, there was an increase in the number of mutant FLAG-positive cybrids as compared to the mock transfectants in mixed cultures. These findings indicate that the modulation of mitochondrial ATP synthase activity via expression of mutant or wild-type MTATP6 from the nucleus can affect cell growth and override the effect of the mtDNA genotype.
There was no marked difference in Ki-67-positive cells (a proliferation marker) or in the cell cycle profiles between mutant and wild-type cybrids. Moreover, there was no difference in Ki-67-positive tumor cells derived from cybrids. These results indicate that the apparent growth advantage is not due to the enhancement of cell proliferation.
Lower frequency of apoptosis of mutant cybrids in vitro and in vivo Mutant cybrids with mutant mtDNA or cybrid transfectants with the nuclear version of mutant MATP6 exhibit alterations in energy metabolism. Then the question is why cells with an energy disadvantage increased faster. Even when the glycolytic pathway is enhanced, the decline in oxidative phosphorylation should be more predominant in energy metabolism. Nevertheless, no difference in the frequency of the Ki-67-positive cells as a proliferation index among cybrid clones was seen. Additionally, the cell cycle was not accelerated by the decline of energy production. Thus, mutant mtDNA did not confer an advantage in cell proliferation. To explore the molecular mechanism underlying the growth advantage in tumors, we hypothesized that mutant mtDNA may protect cells from apoptosis, and therefore the growth advantage of mutant cybrids may be a consequence of increased survival. To test this hypothesis, apoptosis was shown by three independent methods: terminal deoxy transferase uridine triphosphate nick end labeling (TUNEL) staining, DNA fragmentation and sub-G1 population analysed by flow cytometry. The induction of apoptosis in wild-type cybrids was seen in tumors derived from wild-type cybrids than mutant cybrids.
Relationship of apoptosis with mutant mitochondrial DNA

Apoptosis by energy crisis
Some reports indicate that mutant mtDNA induces apoptosis in vitro and in vivo, whereas other reports suggest that cells possessing mutant mtDNA become tolerant to apoptosis. Thus, the relationship between apoptosis and mutant mtDNA may be confusing. However, bioenergetic crisis in these cells may be at the core of this discrepancy. When decline in energy production reaches the minimum requirement, cells cannot survive. Several mutations derived from mitochondrial disease severely affect energy production, leading to a pro-apoptotic effect. Fibroblasts isolated from patients with a subtype of mitochondrial diseases, Leigh syndrome, undergo apoptosis in glucose-deficient medium (Geromel et al., 2001) , probably because neither glycolysis nor oxidative phosphorylation produces sufficient energy. The fibroblasts detached from the dish and underwent apoptosis even in glucose-rich medium. When cybrid cells carrying mutant mtDNA derived from a Leber's hereditary optic neuropathy (LHON) patient were cultured in glucose-deficient medium, they underwent apoptosis (Ghelli et al., 2003) . Cells with pathogenic mutant mtDNA cannot survive without a sufficient energy supply, thus apoptosis in this case seems to be a consequence of a bioenergetic crisis.
Mice with transient mtDNA depletion in various tissues were obtained by knocking out the Tfam gene. Apoptosis was studied in embryos with homozygous disruption of the Tfam gene and tissue-specific Tfam knockout animals exhibited a severe respiratory chain deficiency in the heart. Massive apoptosis was found in Tfam knockout embryos on embryonic day 9.5.
Moreover, apoptosis was increased in the heart of tissuespecific Tfam knockouts (Wang et al., 2001) . Additionally, mice expressing a proofreading-deficient version of mitochondrial DNA polymerase g accumulated mtDNA mutations, and the levels of the accumulated mutations correlated with the induction of apoptotic markers (Kujoth et al., 2005; Trifunovic et al., 2005) . These data provide in vivo evidence that the respiratory chain deficiency predisposes cells to apoptosis.
Development of tolerance to apoptosis by mutant mitochondrial DNA An immortalized human fibroblast cell line carrying wild-type mtDNA underwent apoptosis in a high concentration of molecular oxygen. In contrast, its r0 exhibited a marked resistance to apoptosis . Additionally, r0 cells showed a stronger resistance to irradiation than the other two cell lines (Tang et al., 1999) . r0 cells were more resistant to apoptosis-inducing agents than parental cells in vitro (Singh et al., 1999; Wang et al., 2001) . In these experiments, parental cells or the other cell lines were used as controls. One should bear in mind that it is highly possible to introduce considerable mutations into nuclear genes of r0 cells by long exposure to EtBr during the isolation of a r0 cell line. Nevertheless, these consistent results obtained from various lines of research suggest that they may be negligible.
As mentioned above, in vivo r0 or mtDNA-mutant cells are more sensitive to apoptosis, while r0 cells in culture are more resistant to various apoptotic stimuli. This discrepancy may be explained as follows: cultured r0 cells may adapt to cope with the bioenergetic crisis conditions perhaps because by enhancing the activity of the glycolytic pathway. However, in vivo cells cannot adapt in response to a transient depletion. The process of malignant transformation usually takes a long time. Thus, cancer cells selected during this process are likely better adapted to cope with the energetic demands. Since cybrid cells were derived from r0 cells, they should also be fully adapted. Thus, mtDNA-mutant cybrids are more resistant to apoptosis induced by various stimuli. It remains unclear why r0 and mtDNA-mutant cybrid cells are more resistant to induction of apoptosis at the molecular level.
To understand the molecular mechanism underlying the association between decline of an energy production and sensitivity to apoptosis, it is important to know the expression profiles of nuclear genes. Transient depletion of mtDNA or treatment with mitochondrial poison CCCP initiates mitochondrial stress signaling, which operates through altered Ca 2 þ homeostasis. In myoblasts and human lung carcinoma cells, mitochondrial stress signaling activates calcineurin and a number of Ca 2 þ -responsive factors including activating transcription factor, nuclear factor of activated T cells, CCAAT enhancer-binding protein/d and cAMP-responsive element binding protein. Additionally, protein kinase C and mitogen-activated protein kinase are also activated. Nuclear gene targets including those involved in Ca 2 þ storage/release, glucose metabolism, oncogenesis and apoptosis are upregulated. Mitochondrial stress in both the myoblasts and lung carcinoma cells induced morphological changes and invasive phenotypes (Biswas et al., 2005) . It is important to investigate the molecular mechanism underlying tolerance to apoptosis from the aspects of nuclear gene expression and regulation.
Mitochondrial DNA mutations confer tolerance to anticancer drugs Emergence of drug resistance is a critical problem for chemotherapy, but the mechanisms underlying this phenomenon are not completely understood. Most anticancer drugs are inducers of apoptosis. As mentioned above, mutant mtDNA in cybrids confer resistance to apoptosis. When cybrids were treated with cisplatin, a typical anticancer drug, mutant cybrids were more resistant to apoptosis than the wild-type .
Another report supports our results that mutant cybrids are more resistant to anticancer drugs. r0 cells are extremely resistant to adriamycin and photodynamic therapy (Singh et al., 1999) and cisplatin (Qian et al., 2005) . Tolerance to etoposide was found even by the transient depletion of mtDNA (Biswas et al., 2005) .
Interestingly, ATP synthase is downregulated in some 5-fluorouridine (5-FU)-resistant cells, which also showed decreased ATP synthase activity and reduced Contribution of mutant mtDNA in tumorigenesis S Ohta intracellular ATP content (Shin et al., 2005) . When 5-FU sensitivity was compared with ATP synthase activity in six different human colon cancer cell lines, positive correlation was observed. The bioenergetic dysfunction of mitochondria has been reported as a hallmark of many types of cancers; that is, downregulation of ATP synthase b-subunit expression in liver, kidney, colon, squamous esophageal, and lung carcinomas, as well as in breast and gastric adenocarcinomas (Cuezva et al., 2002 (Cuezva et al., , 2004 Isidoro et al., 2004) . Thus, decreased ATP synthase activity may be associated with resistance to some anticancer drugs. Tolerance to anticancer drugs is due not only to the decline of ATP synthase activity, but rather to alterations in mitochondrial activity. We constructed cybrids harboring mutant mtDNA derived from pancreatic cancer cells. Mutant mtDNA have a mutation at cytochrome c oxidase or the subunit 4 of complex I (ND4). The cybrids were strongly resistant to cisplatin and 5-FU in vivo and in vitro ( Figure 5 ) (manuscript in preparation). Mitochondria are directly involved in apoptosis by releasing factors involved in the initiation, regulation and execution of apotosis (Ohta, 2003) . Members of the bcl-2 family regulate apoptosis on mitochondria. To understand the link between mitochondrial dysfunction and apoptosis at the molecular level, the response profiles of these factors to mitochondrial dysfunction will be investigated. Alternatively, it seems important to highlight cross-talk between the nucleus and mitochondria. The expression of apoptosis regulators may be influenced by dysfunctional mitochondrial through a decrease in ATP, a Ca 2 þ signaling or an increase in lactate or pyruvate by enhancing glycolysis.
Concluding remarks
Methods that had been developed to clarify the responsibility of mutant mtDNA in mitochondrial diseases were applied to investigate its role in tumorigenesis. Cybrids containing a common nucleus and mtDNA with a pathogenic mutation revealed an apparent advantage in growth when transplantated into nude mice. This advantage is related to alterations in mitochondrial activity, but not secondary mutations in the nuclear genome. However, tumors formed by cybrid transplantation may differ in many ways from naturally occurring cancers. More careful investigation will be required to understand the veritable roles of mtDNA in cancer. Additionally, we addressed the role of mutant mtDNA in conferring tolerance to anticancer drugs. By understanding the molecular mechanism of how to gain tolerance, mtDNA will be extensively investigated for clinical application in the light of apoptosis.
